LGND News and Press, Ligand Pharmaceuticals Incorporated From 11/08/23

Raising 2023 Guidance Investor and Analyst Day to be held on Tuesday December 12th in New York City Conference call begins at 4:30 p.m. Eastern Time today Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three and nine month...

Evotec SE (EVO) is expected to report $-0.03 for Q3 2023 Amplifon (AMFPF) is expected to report for Q3 2023 Compass Therapeutics Inc. (CMPX) is expected to report $-0.11 for Q3 2023 Astronics Corp. - Class B (ATROB) is expected to report for Q4 2023 Charge Enterprises Inc. (CRGE) ...

Ligand Pharmaceuticals Incorporated (LGND) is expected to report $0.36 for Q3 2023

2023-11-07 12:10:02 ET More on Ligand Pharmaceuticals Ligand: Nothing Exciting Stands Out Ligand Pharmaceuticals acquires 13% of soticlestat royalties from Ovid Therapeutics for $30M Ligand Pharmaceuticals closes acquisition of assets of Novan Seeking Alpha&#...

COLUMBUS, Ohio, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic breast cancers harboring ESR1 mutations, today announced that a case report detailing a durable compl...

2023-11-05 23:46:57 ET In the upcoming week of November, investors can anticipate a flurry of quarterly reports from major companies, promising significant market activity. Notable among them is Disney ( NYSE: DIS ), a household name set to disclose its financial performance. ...

2023-11-01 08:34:25 ET More on Ligand Pharmaceuticals Ligand: Nothing Exciting Stands Out Ligand Pharmaceuticals acquires 13% of soticlestat royalties from Ovid Therapeutics for $30M Ligand Pharmaceuticals closes acquisition of assets of Novan For further det...

TZIELD is the first and only FDA approved treatment to delay the onset of Stage 3 type 1 diabetes Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that it has acquired Tolerance Therapeutics, Inc. (“Tolerance Therapeutics”) for $20 million in cash. To...

Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) will report third quarter 2023 financial results after the close of the U.S. financial markets on Wednesday, November 8, 2023, and will hold a conference call at 4:30 p.m. Eastern Time that same day to discuss financial results and provide a ge...

2023-10-18 11:05:36 ET More on Ligand Pharmaceuticals, Ovid Therapeutics, etc. Ovid Therapeutics: The GABA Gambit In Seizure Wars Ligand: Nothing Exciting Stands Out For further details see: Ligand Pharmaceuticals acquires 13% of soticlestat royalties from Ovid T...